BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

Protein degradation company C4 and gene therapy play 4D Molecular each raised venture rounds that included crossover investors, suggesting each company could soon join an IPO queue that has burgeoned in recent weeks. 4D had...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

Catalent Inc. (NYSE:CTLT) said Manja Boerman will become president of cell and gene therapy, succeeding Pete Buzy, who will continue as chairman of the gene therapy business. Boerman was president of the biotech’s European biologics...
BC Innovations | Nov 14, 2019
Emerging Company Profile

Cedilla: degrading proteins by modulating protein stability

While most protein degradation companies are developing bifunctional molecules that directly induce ubiquitin-mediated degradation, Cedilla is taking a different approach with monovalent small molecules that trigger a broader range of degradation mechanisms. “The concept of...
BC Extra | Oct 23, 2019
Clinical News

Arvinas clears key hurdle, showing PROTACs orally bioavailable in clinic

Putting to rest concerns regarding oral bioavailability, Arvinas showed that its first two proteolysis-targeting chimeras achieved serum levels predicted to be efficacious. Wednesday’s presentation of Phase I data of ARV-110 for metastatic castration-resistant prostate cancer...
BioCentury | Sep 6, 2019
Emerging Company Profile

Cullgen: boosting the breadth of E3 ligases for protein degradation

Cullgen is expanding the toolbox of E3 ubiquitin ligases that can be used to target and degrade cancer-associated proteins by looking beyond widely used ligases. With its ubiquitin-mediated, small molecule-induced targeted elimination (uSMITE) technology, Cullgen...
BC Extra | Jul 8, 2019
Company News

July 8 Company Quick Takes: Merck, Skyhawk in discovery deal; plus MorphoSys, BioMarin, Roche-Spark and Hanmi

Skyhawk, Merck in neurology, cancer deal  Skyhawk Therapeutics Inc. (Waltham, Mass.) and Merck & Co. Inc. (NYSE:MRK) parterned to discover, develop and commercialize small molecules capable of modulating RNA splicing discovered using Skyhawk’s SkySTAR platform...
BioCentury | Jul 3, 2019
Emerging Company Profile

Kymera: a systematic approach to protein degradation

With a computational drug discovery platform and a proprietary library of E3 ligases and binders, Kymera believes it can accelerate the discovery and development of protein degraders. Protein degradation is entering the mainstream as a...
BC Extra | May 6, 2019
Company News

Skyhawk signs neuro deal with Takeda as it prepares to expand its partnered indications

Skyhawk signed its third major deal in a year, this time with Takeda. Like its first two partnerships, the focus will be in neurology, but Skyhawk is in discussions with companies that could help extend...
BC Innovations | Apr 11, 2019
Emerging Company Profile

Nurix: Two sides of protein degradation

Nurix is flipping the concept of targeted protein degradation on its head. In addition to the usual approach of inducing target destruction, the company has technology that can block E3 ligase activity and increase a...
BC Extra | Mar 14, 2019
Company News

Management tracks: Sandoz CEO steps down, C4T hires NIBR's Crystal as CMO

Richard Francis said he will step down as CEO of Sandoz , the biosimilars and generics unit of Novartis AG (NYSE:NVS; SIX:NOVN), effective March 31. Francis said Thursday, "As we announced earlier this year, Sandoz is...
Items per page:
1 - 10 of 81